🤖 Search 5,000+ AI tools Ask our bot for help →

Discover the latest tools and trends in AI 🔮

Join 60,000+ subscribers including Amazon, Apple, Google, and Microsoft employees reading our free newsletter.

[email protected] Subscribe

DELFI Diagnostics secures equity investment from Merck fund

DELFI Diagnostics secures equity investment from Merck fund
DELFI Diagnostics secures equity investment from Merck fund

DELFI Diagnostics, a Palo Alto-based health tech firm, secured an undisclosed equity investment from the Merck Global Health Innovation Fund (GHIF).

The funds will be utilized to advance the development and commercialization of DELFI’s cancer detection solutions.

Led by CEO Susan Tousi, DELFI Diagnostics aims to leverage advanced machine-learning and whole-genome sequencing data for cancer detection via fragmentomics.

The company’s FirstLook Lung test, which detects lung cancer via cfDNA fragment patterns, has shown 80% sensitivity and a 99.8% negative predictive value in validation studies.

Susan Tousi noted, "This investment will help propel our fragmentomics and AI technologies, potentially enabling early cancer detection with high precision at a disruptive price."

Comments